Invasive lobular carcinoma is characterized by IL33-high differentiated endothelium and IL33 receptor-positive mast-cell enrichment

Breast cancer is not a single disease but a collection of distinct conditions that behave in different ways. Among these, invasive lobular carcinoma stands out as a unique and often misunderstood form. Unlike the more common invasive ductal carcinoma, which tends to grow in tight, cohesive clusters of cells, lobular cancer lacks a specific glue-like protein called E-cadherin. Without this protein, the cancer cells do not stick together; instead, they drift apart and infiltrate the surrounding breast tissue in long, single-file lines. This subtle difference in how the cells move and arrange themselves has long puzzled doctors, particularly because lobular cancer often returns many years after treatment, long after the standard five-year check-up window has closed. To understand why this happens, scientists must look beyond the cancer cells themselves and examine the environment in which they grow, specifically the network of tiny blood vessels that feed the tumor and the immune cells that wander through the tissue.

A new study by Jules Cohen at Stony Brook University investigates this hidden environment, focusing on a specific signaling molecule called IL33 and the immune cells that respond to it. IL33 is a protein naturally found in the lining of healthy, mature blood vessels, acting as a marker of a calm, stable state. When blood vessels are forced to grow rapidly to feed a tumor, they lose this calm marker and become active and sprouting. The study also looks at mast cells, a type of immune cell that carries a receptor capable of listening for IL33. The central question was whether lobular cancer preserves a more normal, stable blood vessel environment compared to ductal cancer, and if this environment attracts a specific population of mast cells that might influence the disease's behavior.

By analyzing genetic data from thousands of patients across three major international databases, the researchers found a clear and consistent pattern. Lobular cancer tumors indeed possess a blood vessel network that looks more like the healthy tissue found in normal breasts. These tumors retain high levels of IL33 in their blood vessel linings and show fewer signs of the frantic, sprouting growth seen in ductal cancers. At the same time, lobular tumors are enriched with mast cells that carry the receptor for IL33. This creates a distinct ecosystem where the blood vessels remain relatively quiet and mature, while a specific type of immune cell gathers nearby. The study ruled out the idea that these differences were simply due to lobular cancer having more blood vessels overall; even when the total number of vessels was accounted for, the lobular tumors still showed this unique, stable state.

The researchers also used advanced techniques to map exactly where these cells are located within the tissue. They confirmed that the IL33 protein is found specifically in the mature, non-sprouting parts of the blood vessels, while the mast cells cluster in these same vessel-rich areas. This spatial arrangement suggests a coordinated relationship between the blood vessels and the immune cells, a feature that is much less pronounced in ductal cancer. The study further explored whether this environment affects patient survival. They discovered that within lobular cancer, tumors that showed signs of aggressive, sprouting blood vessels had significantly worse outcomes. Conversely, the tumors that maintained the calm, IL33-rich environment tended to have better survival rates. This finding held true even when the researchers looked at ductal cancers, where a small subset of tumors with highly sprouting vessels also faced much higher risks of death.

While the study provides a detailed map of this unique landscape, it stops short of proving exactly how these cells talk to one another or how this environment causes the cancer to behave the way it does. The data shows a strong association between the presence of these mature vessels and mast cells and the specific biology of lobular cancer, but it does not yet confirm that one causes the other. The researchers suggest that the loss of the glue protein in lobular cancer might allow the tumor to slip through existing tissue without needing to build new, chaotic blood vessels, thereby preserving the quiet environment that attracts these specific immune cells. This distinct vascular-immune ecosystem may explain why lobular cancer spreads differently and returns later than other types. The work highlights that understanding the neighborhood a tumor lives in is just as important as understanding the tumor itself, offering a new way to think about why this specific form of breast cancer remains so challenging to predict and treat.